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Introduction
When pharmacists, nurses, and other health care workers are occupationally exposed to 
antineoplastic drugs, they are at risk for a range of toxic effects, including, but not limited to, 
adverse reproductive outcomes (Connor and McDiarmid, 2006). To address those risks, 
several organizations have issued safety guidelines regarding the handling of hazardous 
drugs. The American Society of Hospital Pharmacists (now the American Society of Health 
System Pharmacists [ASHP]) has published recommendations since 1983 (Stolar, Power, & 
Viele, 1983) and released its most recent revision in 2006 (ASHP, 2006). The Oncology 
Nursing Society (ONS) first published guidelines in 1984, and has continued to produce 
publications and courses on the topic (Polovich, 2011; Neuse et al., 2013; Polovich, Olsen, 
& LeFebvre, 2014). The Occupational Safety and Health Administration (OSHA) published 
its first guidelines in 1986 and then updated them in 1996, 1999, and gave guidance as 
recently as 2016 (https://www.osha.gov/SLTC/hazardousdrugs/
controlling_occex_hazardousdrugs.html). The National Institute for Occupational Safety and 
Health (NIOSH) reviewed the research in this area and issued recommendations for how to 
handle hazardous drugs in 2004 (Centers for Disease Control and Prevention, 2004). A 
forthcoming update is anticipated to include the hundreds of studies done since that time and 
make recommendations based on a growing body of evidence that there are adverse effects 
from occupational exposure to hazardous drugs.
While federal agencies recognize the NIOSH recommendations, they defer regulation to 
state governments. In a few states during the last decade, nurses and other advocates have 
successfully fought for safe-handling legislation that gives the NIOSH recommendations the 
force of law. Washington state was the first to act, enacting a law in 2011 that covers all 
medications defined as hazardous by NIOSH. California passed a similar law in 2013, which 
covers antineoplastic drugs only. North Carolina passed a safe-handling law in 2014 – 
although, as we discuss below, the rulemaking process was unsuccessful, and that state’s law 
is now effectively a dead letter. Safe-handling bills are currently advancing in the legislatures 
of Massachusetts, Michigan, and New Jersey.
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In the brief case studies that follow, we present three different examples of states moving 
recommendations into policy.
Washington: The Pioneer Effort
In 2010, investigative reporter Carol Smith had been researching the dangers of hazardous 
drugs and met an advocate named Chelsea Crump (Smith, 2010). Chelsea recounted how her 
mother, Sue Crump, had been diagnosed with cancer after working as a pharmacist for many 
years with minimal protection from hazardous drugs. Indeed, even while Sue underwent 
treatment for her cancer, Chelsea noted that the nurses were not wearing the recommended 
personal protective equipment, despite national guidelines.
Armed with this story, Chelsea approached two state legislators and asked for a state law 
that would require healthcare facilities to follow the NIOSH guidelines. In 2011, Governor 
Christine Gregoire signed two bills into law: one requiring the adoption of NIOSH 
guidelines for all institutions where hazardous drugs were handled, and the other to maintain 
a database of personnel who handle hazardous drugs (Eisenberg, 2016). While such 
databases exist in Europe, none had previously been required in the United States.
The Washington State hazardous drug law was given to the Department of Labor and 
Industries (L&I) to develop the rule-making process. A multidisciplinary Hazardous Drug 
Advisory Committee was formed, with members representing employers and employees 
from large hospitals, retail pharmacies, and private medical practices. Disciplines included 
pharmacists, industrial hygienists, physicians, nurses, and a representative from a 
manufacturer of Closed System Transfer Devices (CSTDs). The road to implementation was 
filled with resistance, particularly from employers who felt the NIOSH guidelines were too 
restrictive and would be too costly to implement. Several versions of the rules were written 
and revised, and the original timeline for implementation was lengthened to allow for 
hospitals to budget for costly pharmacy renovations related to required ventilator controls. 
As Seth Eisenberg, one of the three nursing members of the worker sub-committee, 
commented at the end of one tumultuous meeting, “If it had been easy and cheap, they 
would have done this a long time ago.”
The hazardous drug rule was officially adopted by L&I on January 3, 2012. The 
implementation timeline was divided into three stages: Stage I required each organization to 
develop and implement a hazardous drug control program by January 1, 2015. Stage 2 
required employers to provide hazardous drug training by July 1, 2015. And Stage 3 
required hospitals to install appropriate ventilation and biologic safety cabinets by January 1, 
2016 (Hazardous Drug, 2016). Despite being the first state to pass a hazardous drug law, 
L&I has not yet instituted routine inspections of healthcare facilities.
North Carolina: The Pitfalls of Rulemaking
In North Carolina legislative work which began in 2013 advanced as far as law (2014) but 
the rule that resulted (2015) is not currently enforceable. Legislative work in North Carolina 
was initiated by the policy arm of a national medical device company, which invested in a 
local law firm with extensive expertise in regulation and healthcare. With their support, 
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individual nurses and pharmacists, representatives of healthcare facilities, and state and 
national advocates were invited to discuss legislation in the Spring of 2013. Following in the 
footsteps of California with a focus only on anti-neoplastic drugs, HB644 was drafted. 
Those invited to the table to discuss the effort sought buy-in from the local chapters of the 
Oncology Nursing Society and the North Carolina Nurses Association and vested 
individuals. Op-eds were written in the local newspapers and calls to local officials were 
made. Slight revisions were made to the bill’s language and it passed in the NC House in 
2013. In July of 2014, the bill passed in the Senate (An Act Related to the Handling of 
Antineoplastic Agents, 2014). The bill mandated that a group of stakeholders, including 
nurses, be convened as the North Carolina Department of Labor developed rules for the 
enforcement of the law. Over the course of 2015, the NC Department of Labor held two 
public forums and one public comment period, but to the dismay of those invested in the 
issue, a true stakeholder group was never formed. The rules were published in the fall of 
2015 and read that the NIOSH recommendations should be followed unless they were in 
conflict with state-specific rules codified in the North Carolina Administrative Code or any 
federal code, in which case the current code should supersede the NIOSH recommendations 
(North Carolina Office of Administrative Hearings, 2015). Recognizing that this was not a 
measurable change and that a true stakeholder group had not been convened, advocates sent 
21 letters of opposition within 24 hours of the publication of the rules. According to North 
Carolina law, when at least ten letters of opposition are sent after rules are published, the 
topic is sent back to the legislature for further review. Strategic conversations are taking 
place in North Carolina now about how best to proceed with this effort.
Michigan: New Legislative and Regulatory Paths
In Michigan, both legislative and regulatory efforts have advanced. In March 2015, after 
conferring with a broad coalition of oncology nurses, pharmacists, and industry partners, 
Senator Jack Brandenburg (R-Harrison Township) introduced Senate Bill 237 with two 
Republican co-sponsors (Michigan Senate, 2015). The bill contains language similar to the 
bill enacted in Washington State. At press time, the bill has been referred to the Health 
Policy Committee; no hearing has been scheduled. Oncology Nursing Society members have 
met with state legislators and penned op-eds in local papers to encourage consideration of 
the bill.
Distinct from the legislative effort, the Michigan Occupational Safety and Health 
Administration (MiOSHA) has launched a program focused on hazardous drugs (Michigan 
Occupational Safety and Health Administration, 2016). This new program has been 
informed by survey data obtained from members of the Oncology Nursing Society who 
reside in Michigan (He, Mendelsohn-Victor, McCullagh, & Friese, 2016). Launched in June 
2016, the program consists of outreach and education to affected employers, followed by 12 
planned programmed inspections by MiOSHA’s industrial hygienists. Identified worksites 
include facilities where hazardous drugs are prepared and administered, including oncology 
practices, non-oncology infusion centers, urology offices, and veterinary offices. The 
inspections will focus on state and federal guidance that minimize the exposure to hazardous 
drugs and adherence to established standards.
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What if you don’t live in one of the states taking legislative action but want to promote 
policies that support safer handling of antineoplastic and/or hazardous drugs? First, take a 
look at the policies within your own hospital or clinic. Are they consistent with current 
NIOSH recommendations? If not, consider a practice group working on moving your 
clinical area into compliance (Walton et al., 2012). Be aware that in 2018, the United States 
Pharmacopeial Convention’s new Chapter 800, which covers hazardous-medication 
handling, will be enforceable by the Food and Drug Administration and state boards of 
pharmacy (Polovich, 2017). State boards of pharmacy will need to consider harmonizing 
regulations with the requirements of USP 800. Get involved with your professional 
organizations- your local ONS chapters, your state based nursing organizations and tell those 
advocating for you that these are issues you care about. Work with others within and outside 
of nursing to advocate for change in your state if you decide to pursue legislative efforts. 
Consider as well regulatory approaches like those in Michigan.
As a nurse, you are a well-trained educator. Consider educating your legislators and the 
public about this issue through letters, calls, visits and writing op-eds for local newspapers. 
When educating, share personal stories and be prepared to meet some resistance from those 
within and outside of nursing about associated costs and workflow changes. Most of all, get 
involved and help make the changes you want to see in your state and for the safety of all of 
those who come into contact with hazardous drugs.
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• Safety guidelines for handling of hazardous drugs exist but are rarely 
enforced from a regulatory standpoint.
• The authors share their legislative and regulatory experiences in North 
Carolina, Washington, and Michigan.
• Counsel is given to those looking to be active in legislative and regulatory 
efforts in their states.
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